Cancer and a host of other diseases manifest on a molecular level through specific biomarkers, including proteins, nucleic acids such as DNA or RNA, and various other molecular entities. The challenge with these biomarkers lies in their infinitesimal concentrations during the disease’s nascent phase, often evading detection by existing diagnostic tools. Addressing this, the newly developed sensor harnesses a multi-disciplinary approach merging nanotechnology, gene editing, and nonlinear optics to amplify detection capabilities without relying on molecular amplification methods traditionally used in biomarker assays.

At the heart of this sensor is the phenomenon known as second harmonic generation (SHG), a nonlinear optical process wherein incident photons interacting with certain materials are effectively converted into photons of twice the energy — or half the wavelength. The sensor employs molybdenum disulfide (MoS₂), a two-dimensional semiconductor distinguished by its robust SHG response. By leveraging the MoS₂’s properties, the device creates a platform where subtle biochemical interactions translate directly into measurable optical signals, circumventing common issues with background noise that plague many light-based assays.

To precisely modulate the interaction distance essential for enhancing SHG signals, the team implemented DNA tetrahedrons as nanoscopic scaffolds. These tetrahedral structures are meticulously self-assembled from DNA strands, forming rigid, pyramid-like shapes with nanometer precision. Quantum dots, semiconductor nanoparticles renowned for their size-tunable optical characteristics, were tethered to these DNA frameworks. This arrangement enables fine control over the spatial orientation and proximity of quantum dots relative to the MoS₂ surface, thereby dramatically boosting the local electromagnetic field and, consequently, the SHG intensity.

The sensor’s biomarker specificity and detection mechanism owe much to the integration of CRISPR-Cas12a, a precise gene-editing protein programmed to identify target nucleic acid sequences indicative of disease biomarkers. Upon recognizing its target, Cas12a activates collateral cleavage activity, slicing the DNA strands anchoring the quantum dots. This cleavage disrupts the engineered nanostructure, precipitating a measurable decrease in SHG signal. The direct correlation between the presence of the biomarker and SHG signal modulation endows the sensor with remarkable sensitivity and specificity, enabling detection without the need for traditional amplification methods such as PCR.

This amplification-free detection is a profound leap forward, as conventional biomarker assays often entail time-consuming and costly amplification cycles to elevate the signal beyond detectable thresholds. By contrast, the current technology’s design — combining optical nonlinearity for noise suppression, nanometer-scale engineering for signal enhancement, and molecular precision via CRISPR — fosters rapid and accurate biomarker quantification directly from clinical samples. Such efficiency is poised to redefine the landscape of molecular diagnostics.

In practical application, the team focused on miR-21, a microRNA implicated as a lung cancer biomarker. Initial tests in buffer solutions established baseline sensitivity, followed by validation within human serum extracted from lung cancer patients. The sensor demonstrated exceptional performance, effectively distinguishing the target microRNA from a milieu of structurally similar RNA molecules present in serum, underscoring both its specificity and robustness. This real-world applicability suggests a viable path toward clinical translation.

Beyond lung cancer, the sensor’s modular design and programmable DNA constructs imply versatility across a plethora of diseases and biomarkers. The detection scheme could readily adapt to viruses, bacterial pathogens, and other disease-relevant molecules, unlocking potential applications in infectious disease surveillance, environmental monitoring, and neurodegenerative disease diagnostics, such as Alzheimer’s biomarkers. This universality underscores the sensor’s broad impact potential across multiple domains of healthcare and beyond.

Looking forward, the research team has ambitious plans to transform this laboratory-scale technology into a portable, user-friendly device. Miniaturizing the optical setup and integrating it into a compact form factor could enable bedside or point-of-care testing, expanding accessibility to underserved and remote locations lacking sophisticated laboratory infrastructure. Such advancements would democratize early disease detection, empowering timely interventions and personalized patient management.

The union of DNA nanotechnology, quantum dot-enhanced nonlinear optics, and CRISPR-based molecular recognition represents a triumph of interdisciplinary innovation. This synergy facilitates an elegant sensing architecture that balances speed, precision, and minimal complexity—characteristics critical for next-generation diagnostic tools. As the technology matures and moves toward commercialization, its capacity to reshape cancer diagnostics and monitoring stands to significantly impact patient outcomes and healthcare economics.

Published in the journal Optica, under the title “Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces,” this research marks a seminal contribution to the field of biomedical optics. The detailed mechanisms and experimental validations outlined exemplify how fundamental physics and molecular biology can converge to create disruptive technologies in medicine.

In summary, the development of this highly sensitive SHG-based biosensor integrates the nanoprecision of DNA assembly, the optical enhancement of quantum dots, and the molecular specificity of CRISPR-Cas12a. This marriage of techniques enables the amplification-free detection of cancer biomarkers at previously unattainable sensitivity levels, bringing the prospect of rapid, accurate, and non-invasive cancer detection closer to reality. As such, it holds tremendous promise for revolutionizing how clinicians detect and monitor diseases, ultimately facilitating earlier interventions and improving survival outcomes worldwide.

Subject of Research: Cancer biomarker detection using light-based sensing technologies.

Article Title: Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces

Web References:

• DOI Link
• Optica Journal Homepage

References:
B. Du, X. Tian, S. Han, Y. Liu, Z. Chen, Y. Liu, L. Li, Z. Xie, L. Gao, K. Jiang, Q. Jiang, S. Chen, H. Zhang, “Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces” Optica, 13 (2025).

Image Credits: Han Zhang, Shenzhen University

Keywords: Cancer research, Quantum dots, Metasurfaces, Clinical medicine

The cornerstone of this research lies in a comparative analysis of three FDA-approved automated CTC isolation systems—each employing distinct methodologies: marker-based, size-based, and hemocyte extraction–based approaches. Testing these platforms on identical patient blood samples, the research team highlighted the superiority of the hemocyte extraction–based system branded as CTCeptor, a cutting-edge technology originally developed by DGIST and commercialized by CTCELLS. Notably, CTCeptor outperformed its counterparts in capturing heterogeneous tumor cell populations, overcoming intrinsic limitations faced by marker- and size-based methods that often miss subsets of cancer cells with variable marker expression or deformability.

Delving deeper into the performance metrics, the CTCeptor system demonstrated a remarkable capacity by detecting at least 15 times more circulating tumor cells in early-stage breast cancer patients compared to conventional technologies like CellSearch and Parsortix. Even more striking was the device’s ability to isolate circulating cancer-associated fibroblasts at an average frequency that far exceeded CTC detection rates—approximately tenfold higher. This finding underscores the significance of capturing cCAFs, which are key stromal components that modulate tumor progression, metastatic potential, and therapeutic resistance, yet have traditionally been neglected in liquid biopsy assays.

The implications of being able to analyze both tumor cells and their supportive microenvironment through a single blood draw are profound. Tumor-associated fibroblasts contribute significantly to the extracellular matrix remodeling, immune evasion, and maintenance of cancer stem cell niches, elements crucial for tumor growth and heterogeneity. The discovery of heterogeneity in CAF markers within blood-derived cells, as identified by the CTCeptor technology, represents a novel insight that can refine diagnostic precision and inform tailored treatment strategies that consider tumor-stromal interactions.

A pivotal aspect of this study involved rigorous testing across diverse cancer cell lines, including breast, lung, and ovarian cancers, as well as a breast cancer-derived CTC line. Across these various models, CTCeptor consistently demonstrated high recovery rates and robust performance irrespective of cell size—ranging from 13 to 17 micrometers—and EpCAM (epithelial cell adhesion molecule) expression levels. This is particularly noteworthy given that many traditional size- or marker-dependent technologies suffer from variable efficiency when confronted with tumor cell heterogeneity or cellular plasticity, such as changes in epithelial-mesenchymal transition states.

In contrast, size-based filtration methods illustrated inherent limitations. Such platforms can suffer from reduced capture efficiency due to physical deformability of certain tumor cells, which may allow them to escape capture pores or filters designed around fixed size thresholds. This intrinsic drawback highlights the potential for false negatives in clinical diagnostics, an issue ameliorated by the hemocyte extraction–based CTCeptor approach, which leverages a sophisticated cell isolation mechanism accounting for both physical and biological attributes of cancer cells and associated stromal components.

The innovation behind CTCeptor extends beyond mere capture efficiency. By simultaneously isolating tumor cells alongside cancer-associated fibroblasts from the same blood sample, this technology fosters a more comprehensive view of the tumor’s systemic presence and interaction with its microenvironment. This integrative liquid biopsy method holds significant promise for real-time monitoring of tumor evolution, therapeutic efficacy, and early detection of metastatic spread, potentially transforming clinical oncology practice by providing dynamic, individualized patient profiles.

Professor Minseok Kim emphasized the paradigm-shifting nature of this technology, articulating that despite a quarter-century of progress in liquid biopsy, prior efforts predominantly focused solely on tumor cells. The capability to concurrently analyze the tumor microenvironment’s cellular constituents offers unprecedented avenues for understanding tumor biology and pharmacodynamics. Such insights are critical for accelerating drug development pipelines and elevating the precision of personalized cancer therapies, thereby enhancing patient outcomes.

Funding for this landmark study was secured through prestigious grants from the National Research Foundation of Korea’s Mid-Career Project under the Individual Research Support Program, the European Research Council’s Advanced Investigator Grant, INJURMET, and the German Cancer Foundation (DKH) Priority Program on Translational Oncology. The multidisciplinary, international support reflects the global emphasis on advancing liquid biopsy technologies to meet urgent clinical needs.

The research findings have received notable recognition for their technical innovation and academic impact, culminating in publication as the cover story in Analytical Chemistry, a highly respected journal in the field of molecular and analytical sciences. This prominent placement underscores the study’s contribution to both fundamental knowledge and practical applications, positioning the CTCeptor technology as a frontrunner in the ongoing evolution of cancer diagnostics.

Looking forward, the ability to detect and characterize circulating cancer-associated fibroblasts alongside tumor cells may unlock deeper understanding of metastatic niches and mechanisms of chemoresistance. Expanding the repertoire of liquid biopsy analytes represents an exciting frontier that combines molecular biology, engineering, and clinical oncology, promising earlier interventions and dynamic treatment adjustments based on a patient’s unique tumor ecology.

In clinical practice, the integration of such advanced liquid biopsy tools could dramatically reduce the need for invasive tissue biopsies. Given the heterogeneity within tumors and across metastases, blood-based diagnostics offer a minimally invasive and repeatable method to capture the full spectrum of tumor biology over time, ultimately facilitating precision medicine approaches that adapt to tumor adaptation and progression.

Furthermore, the CTCeptor platform’s adaptability across multiple cancer types beyond breast cancer, including lung and ovarian malignancies, highlights its potential as a universal liquid biopsy tool. This versatility broadens its clinical utility, enabling oncologists to monitor various cancers with a single, robust diagnostic platform capable of capturing critical cellular players involved in different tumor microenvironments.

In conclusion, this pioneering research spearheaded by DGIST and collaborators represents a watershed moment in liquid biopsy technology. By simultaneously isolating circulating tumor cells and cancer-associated fibroblasts with unprecedented sensitivity and specificity, the CTCeptor platform enhances the resolution at which cancer can be monitored non-invasively. This technological breakthrough not only advances early diagnosis and treatment response assessment but also paves the way for novel therapeutic strategies that target both tumor cells and their supporting stroma, heralding a new era of personalized oncology.

Article Title: Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer

Web References: https://doi.org/10.1021/acs.analchem.5c02154

Keywords

Tumor cells, Circulating tumor cells (CTCs), Cancer-associated fibroblasts (cCAFs), Liquid biopsy, Tumor microenvironment, Breast cancer diagnostics, Cell isolation technology, Precision medicine, Hemocyte extraction, Cancer heterogeneity, Early cancer detection, Personalized oncology

The innovative study, spearheaded by Li et al., was conducted at a single center between October 2023 and February 2024, enrolling 38 consecutive patients with suspected SLN anomalies. Employing a prospective methodology, the research team meticulously applied both conventional B-mode ultrasonography and the novel HFR CEUS combined with CVI post-processing to assess the diagnostic utility of these imaging modalities rigorously. The incorporation of fine-needle aspiration cytologic or histopathologic examination as a diagnostic gold standard underscored the robustness of their comparative analysis.

Central to the breakthrough is the technology of high-frame-rate contrast-enhanced ultrasound, which capitalizes on microbubble contrast agents and rapid image acquisition rates to visualize lymphatic perfusion dynamics with unprecedented temporal resolution. This technical enhancement enables clinicians to observe the microvascular flow patterns within lymph nodes in real time, capturing subtle differences that traditional ultrasound methods may miss.

Complementing this is contrast vector imaging, a sophisticated image processing technique that quantifies spatially and temporally resolved flow vectors within the enhanced ultrasound images. By translating intricate perfusion patterns into vectorial data, CVI offers a granular, quantitative perspective on lymph node vascularization, illuminating the pathophysiological underpinnings distinguishing malignant from benign nodes.

The study’s findings underscore a stark contrast in perfusion patterns between benign and malignant SLNs. Benign nodes predominantly exhibited centrifugal contrast dispersion, indicative of normal vascular architecture, whereas malignant nodes displayed centripetal and hybrid contrast patterns alongside frequent perfusion defects. These distinct vascular signatures, observable via HFR CEUS combined with CVI, provide a functional biomarker for malignancy with significant diagnostic implications.

Quantitatively, the synergy between HFR CEUS and CVI yielded a kappa coefficient of 0.81 when benchmarked against pathological diagnoses, denoting strong agreement. This surpasses the performance of HFR CEUS alone, which achieved a kappa value of 0.66, suggesting that the adjunctive use of CVI enhances diagnostic confidence and accuracy considerably.

The significance of these results is amplified by the study’s prospective design and the clinical relevance of superficial lymph nodes, which serve as accessible sentinel sites for metastatic spread in numerous cancers. Early and precise characterization of SLN lesions is critical for staging, treatment planning, and prognostication, positioning this imaging approach as an invaluable tool in oncologic care.

Technically, HFR CEUS leverages ultrafast imaging sequences that capture thousands of frames per second, surpassing conventional ultrasound frame rates by an order of magnitude. This advancement mitigates motion artifacts and enables a comprehensive temporal mapping of contrast agent kinetics within lymphoid tissue microcirculation, a feat unattainable with prior imaging protocols.

CVI’s contribution lies in its algorithmic capability to decompose and vectorize complex flow patterns, revealing directional blood flow trajectories and localized perfusion anomalies. This data-driven imaging modality enriches the interpretive framework beyond qualitative assessment, providing clinicians with objective metrics essential for nuanced differential diagnosis.

The integration of these technologies addresses long-standing limitations in lymph node evaluation where conventional B-mode ultrasound lacks sufficient specificity and contrast-enhanced ultrasound alone may fall short in characterizing heterogeneity within the nodal microenvironment. By merging rapid imaging acquisition with sophisticated computational analysis, this dual modality approach signifies a paradigm shift.

Beyond diagnostic superiority, the minimally invasive nature of HFR CEUS combined with CVI offers a patient-friendly alternative to more invasive procedures such as surgical biopsy. The ability to noninvasively monitor lymphatic changes in real time opens avenues for dynamic disease monitoring and personalized treatment adjustments, enhancing clinical outcomes.

However, the study also highlights the necessity for further large-scale validation to determine the reproducibility of these findings across diverse populations and varying clinical settings. Moreover, the standardization of imaging protocols and CVI parameter thresholds will be vital for widespread adoption and integration into routine diagnostic workflows.

The promising results reported herald a new era where real-time, high-resolution vascular imaging merges seamlessly with sophisticated computational tools to decode the complexities of lymph node pathology. This emergent technology stands to influence not only oncologic diagnostics but may also impact the evaluation of inflammatory and infectious lymphadenopathies, broadening its clinical utility.

In summary, the combined employment of high-frame-rate contrast-enhanced ultrasound and contrast vector imaging offers a potent, nuanced, and non-invasive approach to accurately differentiate benign from malignant superficial lymph node lesions. Its potential to enhance diagnostic precision, reduce reliance on invasive procedures, and tailor patient management marks a significant stride forward in medical imaging science.

As the oncology community seeks ever more refined diagnostic tools, the confluence of ultrafast imaging and advanced image processing demonstrated here represents a beacon of innovation. By illuminating the vascular signatures of malignancy with clarity and precision, this technology paves the way for more effective, timely, and personalized cancer care.

Such developments underscore the symbiotic relationship between technological ingenuity and clinical need, exemplifying how incremental scientific progress can culminate in transformative healthcare improvements. With ongoing research and clinical integration, HFR CEUS combined with CVI could soon become a mainstay in the diagnostic arsenal against cancer.

The study by Li et al. thus not only advances the frontier of lymph node imaging but also exemplifies the critical role of multidisciplinary collaboration in pushing the boundaries of diagnostic radiology. As technological capabilities evolve, their translation into clinically impactful solutions represents the hallmark of modern medical research.

Subject of Research: Diagnostic performance of high-frame-rate contrast-enhanced ultrasound combined with contrast vector imaging in detecting benign and malignant superficial lymph nodes.

Article Title: Diagnostic value of high-frame-rate contrast-enhanced ultrasound and contrast vector imaging for superficial lymph node lesions.

Article References:
Li, R., Lan, X., Xie, X. et al. Diagnostic value of high-frame-rate contrast-enhanced ultrasound and contrast vector imaging for superficial lymph node lesions. BMC Cancer 25, 785 (2025). https://doi.org/10.1186/s12885-025-14190-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14190-0